NEKTAR THERAPEUTICS Quarterly Weighted Average Number of Shares Outstanding, Diluted from Q3 2013 to Q2 2024

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
Nektar Therapeutics quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and growth rate from Q3 2013 to Q2 2024.
  • Nektar Therapeutics Weighted Average Number of Shares Outstanding, Diluted for the quarter ending June 30, 2024 was 209M shares, a 10.1% increase year-over-year.
  • Nektar Therapeutics annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 190M shares, a 1.53% increase from 2022.
  • Nektar Therapeutics annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 187M shares, a 2.1% increase from 2021.
  • Nektar Therapeutics annual Weighted Average Number of Shares Outstanding, Diluted for 2021 was 183M shares, a 2.64% increase from 2020.
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 209M +19.2M +10.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-09
Q1 2024 195M +5.87M +3.11% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-10
Q4 2023 190M +2.86M +1.53% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-05
Q3 2023 190M +2.77M +1.47% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 190M +2.86M +1.53% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 189M +3.03M +1.63% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-10
Q4 2022 187M +3.84M +2.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-05
Q3 2022 188M +3.53M +1.92% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 187M +4.1M +2.25% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 186M +4.48M +2.47% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 183M Oct 1, 2021 Dec 31, 2021 10-K 2024-03-05
Q3 2021 184M +5.02M +2.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-04
Q2 2021 183M +4.37M +2.45% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-05
Q1 2021 181M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q3 2020 179M +3.69M +2.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-05
Q2 2020 178M +3.78M +2.16% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-06
Q3 2019 175M +2.7M +1.57% Jul 1, 2019 Sep 30, 2019 10-Q 2019-11-07
Q2 2019 175M -7.74M -4.25% Apr 1, 2019 Jun 30, 2019 10-Q 2019-08-09
Q3 2018 173M +10.1M +6.18% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 182M +26.9M +17.3% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q3 2017 163M +25.5M +18.6% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 155M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q3 2016 137M +4.46M +3.37% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-08
Q1 2016 136M +126K +0.09% Jan 1, 2016 Mar 31, 2016 10-Q 2016-05-04
Q3 2015 133M +454K +0.34% Jul 1, 2015 Sep 30, 2015 10-Q 2015-11-06
Q1 2015 136M +12.1M +9.81% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-04
Q3 2014 132M +16.4M +14.1% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-06
Q1 2014 124M Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-01
Q3 2013 116M Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.